Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bagby

Showing results (111-120 of 140) with videos related to

Pageof 14
Sort By:
Frontiers in Oncology|April 19, 2021
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal AdenocarcinomaSarah J Hartman, Stacey M Bagby, Betelehem W Yacob, et al.
Oncotarget|October 7, 2015
Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenograftsChristopher H Lieu, Peter J Klauck, Patrick K Henthorn, et al.
Oncogene|September 27, 2018
BRAF fusions identified in melanomas have variable treatment responses and phenotypesJacqueline A Turner, Judson G T Bemis, Stacey M Bagby, et al.
Investigational New Drugs|October 27, 2016
Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)Kit Man Wong, Lindsey N Micel, Heather M Selby, et al.
BMC Cancer|November 5, 2020
RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast CancerJohn J Tentler, Julie Lang, Anna Capasso, et al.
Plos One|November 18, 2014
Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancerTodd M Pitts, Timothy P Newton, Erica L Bradshaw-Pierce, et al.
BMC Cancer|February 7, 2018
Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancerPeter J Klauck, Stacey M Bagby, Anna Capasso, et al.
Cancer Research Communications|September 29, 2023
Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic MicroenvironmentJesus Amo-Aparicio, Adrian Dominguez, Shaikh M Atif, et al.
BMC Cancer|October 30, 2022
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancerS Lindsey Davis, Sarah J Hartman, Stacey M Bagby, et al.
Oncotarget|January 18, 2018
The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapyJustin Greene, Anna Nguyen, Stacey M Bagby, et al.
Pageof 14

Showing results (111-120 of 140) with videos related to

Sort By:
Pageof 14
Frontiers in Oncology|April 19, 2021
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal AdenocarcinomaSarah J Hartman, Stacey M Bagby, Betelehem W Yacob, et al.
Oncotarget|October 7, 2015
Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenograftsChristopher H Lieu, Peter J Klauck, Patrick K Henthorn, et al.
Oncogene|September 27, 2018
BRAF fusions identified in melanomas have variable treatment responses and phenotypesJacqueline A Turner, Judson G T Bemis, Stacey M Bagby, et al.
Investigational New Drugs|October 27, 2016
Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)Kit Man Wong, Lindsey N Micel, Heather M Selby, et al.
BMC Cancer|November 5, 2020
RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast CancerJohn J Tentler, Julie Lang, Anna Capasso, et al.
Plos One|November 18, 2014
Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancerTodd M Pitts, Timothy P Newton, Erica L Bradshaw-Pierce, et al.
BMC Cancer|February 7, 2018
Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancerPeter J Klauck, Stacey M Bagby, Anna Capasso, et al.
Cancer Research Communications|September 29, 2023
Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic MicroenvironmentJesus Amo-Aparicio, Adrian Dominguez, Shaikh M Atif, et al.
BMC Cancer|October 30, 2022
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancerS Lindsey Davis, Sarah J Hartman, Stacey M Bagby, et al.
Oncotarget|January 18, 2018
The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapyJustin Greene, Anna Nguyen, Stacey M Bagby, et al.
Pageof 14